Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 4/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2203045 | 0.83 | CETP (0.47) | CETPCYP4F2CYP4A11CYP2C19 | |
| SCHEMBL1421653 | 0.81 | CETP (0.49) | CETPCYP4F2CYP4A11CYP2C19 | |
| SCHEMBL1421573 | 0.80 | CETP (0.45) | CETPCYP4F2CYP4A11CYP2C19 | |
| SCHEMBL1421937 | 0.79 | CETP (0.44) | CETPCYP4F2CYP4A11CYP2C19 | |
| SCHEMBL9972631 | 0.78 | CETP (0.47) | CETPCYP2C19 | |
| SCHEMBL30736687 | 0.78 | CYP4F2 (0.41) | CYP4F2CYP4A11CYP2C19 | |
| SCHEMBL1422218 | 0.77 | CETP (0.43) | CETPCYP4F2CYP4A11CYP2C19 | |
| SCHEMBL3295173 | 0.76 | CYP4F2 (0.38) | CYP4F2CYP4A11CYP2C19 | |
| SCHEMBL727220 | 0.75 | CYP2C19 (0.50) | CETPCYP2C19 | |
| SCHEMBL1764252 | 0.75 | CYP4F2 (0.42) | CYP4F2CYP4A11CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297081-B1 | 1-(2-ETHYL-BUTYL)-CYCLOHEXANECARBOXYLIC ACID ESTER AS AN INTERMEDIATE IN THE PREPARATION OF PHARMACEUTICALLY ACTIVE AMIDES | HOFFMANN LA ROCHE (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-8071803-B2 | Process | HOFFMANN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2297081-A1 | 1-(2-ETHYL-BUTYL) -CYCLOHEXANECARBOXYLIC ACID ESTER AS AN INTERMEDIATE IN THE PREPARATION OF PHARMACEUTICALLY ACTIVE AMIDES | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009153181-A1 | 1-(2-ETHYL-BUTYL) -CYCLOHEXANECARBOXYLIC ACID ESTER AS AN INTERMEDIATE IN THE PREPARATION OF PHARMACEUTICALLY ACTIVE AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| US-20090312569-A1 | NOVEL PROCESS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312569-A1 | NOVEL PROCESS | CYP3A5, MCCC2, CYP3A4 | CETP 683/4885CYP4F2 76/4885CYP4A11 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.